Nateglinide Patent Expiration
Nateglinide is Used for managing blood glucose levels in individuals with diabetes, particularly type 2 diabetes. It was first introduced by Novartis Pharmaceuticals Corp
Nateglinide Patents
Given below is the list of patents protecting Nateglinide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Starlix | US6559188 | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
Sep 15, 2020
(Expired) | Novartis |
| Starlix | US6878749 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
Sep 15, 2020
(Expired) | Novartis |
| Starlix | US6641841 | Tablet composition |
Nov 14, 2017
(Expired) | Novartis |
| Starlix | US6844008 | Tablet composition |
Nov 14, 2017
(Expired) | Novartis |
| Starlix | US5488150 | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them |
Jan 30, 2013
(Expired) | Novartis |
| Starlix | US5463116 | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
Oct 21, 2012
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nateglinide's patents.
Latest Legal Activities on Nateglinide's Patents
Given below is the list recent legal activities going on the following patents of Nateglinide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 10 May, 2013 | US6878749 |
| Post Issue Communication - Certificate of Correction | 22 Jan, 2008 | US6844008 |
| Case Docketed to Examiner in GAU Critical | 17 Jul, 2007 | US6844008 |
| Post Issue Communication - Certificate of Correction | 10 Jan, 2007 | US6641841 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Apr, 2005 | US6878749 |
| Recordation of Patent Grant Mailed Critical | 12 Apr, 2005 | US6878749 |
| Issue Notification Mailed Critical | 23 Mar, 2005 | US6878749 |
| Application Is Considered Ready for Issue Critical | 15 Mar, 2005 | US6878749 |
| Dispatch to FDC | 15 Mar, 2005 | US6878749 |
| Receipt into Pubs | 15 Mar, 2005 | US6878749 |
Nateglinide's Family Patents
Explore Our Curated Drug Screens
Nateglinide Generic API Manufacturers
Several generic applications have been filed for Nateglinide. The first generic version for Nateglinide was by Dr Reddys Laboratories Ltd and was approved on Sep 9, 2009. And the latest generic version is by Cadila Pharmaceuticals Ltd and was approved on Apr 19, 2019.
Given below is the list of companies who have filed for Nateglinide generic, along with the locations of their manufacturing plants worldwide.
1. ALVOGEN
Alvogen Inc has filed for 2 different strengths of generic version for Nateglinide. Given below are the details of the strengths of this generic introduced by Alvogen.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Discontinued | ORAL | N/A | Dec 11, 2015 |
| 120MG | tablet | Discontinued | ORAL | N/A | Dec 11, 2015 |
Manufacturing Plant Locations New
Alvogen's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Alvogen as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
2. CADILA PHARMS LTD
Cadila Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Nateglinide. Given below are the details of the strengths of this generic introduced by Cadila Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Apr 19, 2019 |
| 120MG | tablet | Prescription | ORAL | AB | Apr 19, 2019 |
3. DR REDDYS LABS LTD
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Nateglinide. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 120MG | tablet | Prescription | ORAL | AB | Sep 9, 2009 |
| 60MG | tablet | Prescription | ORAL | AB | Sep 9, 2009 |
4. RISING
Rising Pharma Holdings Inc has filed for 2 different strengths of generic version for Nateglinide. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Jun 18, 2018 |
| 120MG | tablet | Prescription | ORAL | AB | Jun 18, 2018 |
Manufacturing Plant Locations New
Rising's manufacturing plants are situated in 3 countries - United States, Mexico, India. Given below are the details of these plant locations as well as the firm names of Rising as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||
| Mexico |
| |||||||||||||||||||
| India |
| |||||||||||||||||||
5. STRIDES PHARMA
Strides Pharma Global Pte Ltd has filed for 2 different strengths of generic version for Nateglinide. Given below are the details of the strengths of this generic introduced by Strides Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Sep 9, 2009 |
| 120MG | tablet | Prescription | ORAL | AB | Sep 9, 2009 |
Manufacturing Plant Locations New
Strides Pharma's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Strides Pharma as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| India |
| |||||
6. TEVA PHARMS
Teva Pharmaceuticals Usa has filed for 2 different strengths of generic version for Nateglinide. Given below are the details of the strengths of this generic introduced by Teva Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 120MG | tablet | Discontinued | ORAL | N/A | Sep 9, 2009 |
| 60MG | tablet | Discontinued | ORAL | N/A | Sep 9, 2009 |
7. WATSON LABS
Watson Laboratories Inc has filed for 2 different strengths of generic version for Nateglinide. Given below are the details of the strengths of this generic introduced by Watson Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 120MG | tablet | Prescription | ORAL | AB | Mar 30, 2011 |
| 60MG | tablet | Prescription | ORAL | AB | Mar 30, 2011 |
8. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Nateglinide. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Jul 6, 2016 |
| 120MG
(reference standard) | tablet | Prescription | ORAL | AB | Jul 6, 2016 |